Ju Li

Dr. Ju Li


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
JGJin Geng
Jin Geng
CYChenchen Yang
Chenchen Yang
BWBingjian Wang
Bingjian Wang
XZXiwen Zhang
Xiwen Zhang
THTingting Hu
Tingting Hu
JLJu Li
Ju Li

1 April 2017 in Medicine
Verified
Journal Article
Open access
PDF file
JGJin Geng
Jin Geng
YZYanchun Zhang
Yanchun Zhang
BWBingjian Wang
Bingjian Wang
JXJun Xie
Jun Xie
BXBiao Xu
Biao Xu
JLJu Li
Ju Li
A number of studies assessed the prognostic value of HbA1c level in nondiabetic patients with coronary artery disease (CAD). The purpose of this meta-analysis was to assess the association between the HbA1c level and clinical outcomes. We searched PubMed, EMBASE, MEDLINE, and the Cochrane Library from their inception to 10 April 2016. Studies evaluated the outcomes according to HbA1c levels in CAD patients without diabetes mellitus were eligible. Twenty studies involving 22,428 patients were included. In nondiabetic patients with CAD, a high HbA1c level was associated with a higher rate of long-term death (odds ratio 1.76, 95% confidence interval 1.44–2.16, P < .001), and myocardial infarction (MI, odds ratio 1.69, 95% confidence interval 1.07–2.67, P = .026), but not a higher rate of early deaths (odds ratio 1.08, 95% confidence interval 0.92–1.27, P = .359). These findings for death remained the same after sensitivity analyses and the trim and fill method, but the risk difference for MI became nonsignificant after adjustment for potential publication bias. Elevated HbA1c level increased the risks of long-term mortality and MI, but not the risk for early deaths in nondiabetic patients with CAD. High-quality large-scale studies with less bias are needed to confirm these findings.

1 September 2022 in Pharmacogenomics and Personalized Medicine
Verified
Journal Article
Open access
PDF file
HCHongwei Chen
Hongwei Chen
YTYian Tian
Yian Tian
SLShanshan Liu
Shanshan Liu
ZZZhongyuan Zhang
Zhongyuan Zhang
LSLeilei Shen
Leilei Shen
JLJu Li
Ju Li
Background: Rapidly progressive interstitial lung disease (RP-ILD) is a significant complication that determines the prognosis of dermatomyositis (DM). Early RP-ILD diagnosis can improve screening and diagnostic efficiency and provide meaningful guidance to carry out early and aggressive treatment. Methods: A retrospective screening of 284 patients with DM was performed. Clinical and laboratory characteristics of the patients were recorded. The risk factors of RP-ILD in DM patients were screened by logistic regression (LR) and machine learning methods, and the prediction models of RP-ILD were developed by machine learning methods, namely least absolute shrinkage and selection operator (LASSO), random forest (RF), and extreme gradient boosting (XGBoost). Results: According to the result of univariate LR, disease duration is a protective factor for RP-ILD, and ESR, CRP, anti-Ro-52 antibody and anti-MDA5 antibody are risk factors for RP-ILD. The top 10 important variables of the 3 machine learning models were intersected to obtain common important variables, and there were 5 common important variables, namely disease duration, LDH, CRP, anti-Ro-52 antibody and anti-MDA5 antibody. The AUC of LASSO, RF and XGBoost test set were 0.661, 0.667 and 0.867, respectively. We further validated the performance of these three models on validation set, and the results showed that, the AUC of LASSO, RF and XGBoost were 0.764, 0.727 and 0.909, respectively. Based on the results of the models, XGBoost is the optimal model in this study. Conclusion: Disease duration, LDH, CRP, anti-Ro-52 antibody and anti-MDA5 antibody are vital risk factors for RP-ILD in DM. The prediction model constructed using XGBoost can be used for risk identification and early intervention in DM patients with RP-ILD and practical application.

1 July 2021 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
HCHongwei Chen
Hongwei Chen
ZZZhongyuan Zhang
Zhongyuan Zhang
DMDeqian Meng
Deqian Meng
JLJu Li
Ju Li